Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 12/20 | 0.60 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 2/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12548270 | 1.00 | F9 (0.60) | F9ALOX5APFEN1IDH1CCKBR | |
| SCHEMBL1946463 | 1.00 | F9 (0.60) | F9ALOX5APFEN1IDH1CCKBR | |
| SCHEMBL1946460 | 1.00 | F9 (0.60) | F9ALOX5APFEN1IDH1CCKBR | |
| SCHEMBL12548693 | 1.00 | F9 (0.60) | F9ALOX5APFEN1IDH1CCKBR | |
| SCHEMBL1948742 | 0.90 | F9 (0.73) | F9ALOX5APFEN1EPHX2 | |
| SCHEMBL1949000 | 0.90 | F9 (0.73) | F9ALOX5APFEN1EPHX2 | |
| Hydrochloric Acid SCHEMBL1948955 | 0.89 | F9 (0.72) | F9ALOX5APFEN1EPHX2 | |
| SCHEMBL1947611 | 0.88 | F9 (0.66) | F9EPHX2 | |
| Hydrochloric Acid SCHEMBL1947492 | 0.87 | F9 (0.65) | F9EPHX2 | |
| SCHEMBL1949657 | 0.86 | F9 (0.59) | F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | claimed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | claimed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885ALOX5AP 978/4885FEN1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.